OTCMNMRD
Market cap0kUSD
Dec 20, Last price
0.00USD
1D
-99.50%
1Q
-100.00%
Jan 2017
-100.00%
IPO
-100.00%
Name
Nemaura Medical Inc
Chart & Performance
P/E
—
P/S
0.00
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-30.19%
Rev. gr., 5y
%
Revenues
77k
-84.71%
Net income
-14m
L+1.85%
CFO
-8m
L+29.95%
Earnings
Feb 10, 2025
Profile
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | 2015‑03 | |
| Income | |||||||||
Revenues | 77 -84.71% | 504 | |||||||
Cost of revenue | 8,692 | 8,074 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (8,615) | (7,570) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (350) | ||||||||
Tax Rate | |||||||||
NOPAT | (8,615) | (7,220) | |||||||
Net income | (14,144) 1.85% | (13,887) 121.88% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 8,394 | 3,119 | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 16,942 | 19,189 | |||||||
Long-term debt | 3,088 | ||||||||
Deferred revenue | 1,022 | 1,053 | |||||||
Other long-term liabilities | |||||||||
Net debt | 9,925 | 1,439 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (8,452) | (6,504) | |||||||
CAPEX | (376) | (956) | |||||||
Cash from investing activities | (539) | (956) | |||||||
Cash from financing activities | 2,082 | (6,368) | |||||||
FCF | (7,780) | (7,062) | |||||||
| Balance | |||||||||
Cash | 10,105 | 17,749 | |||||||
Long term investments | |||||||||
Excess cash | 10,101 | 17,724 | |||||||
Stockholders' equity | (52,806) | (37,830) | |||||||
Invested Capital | 62,043 | 58,537 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 24,878 | 23,384 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (8,171) | (7,341) | |||||||
EV/EBITDA | |||||||||
Interest | 6,413 | 6,667 | |||||||
Interest/NOPBT | |||||||||